Navigation Links
Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
Date:2/1/2012

Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 11:15 a.m. Eastern Time on February 1, 2012 through 12:00 a.m. Eastern Time on March 1,  2012 by dialing:

Domestic:
(800) 585-8367
International:
(404) 537-3406
Conference ID:
48497482

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "esti
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... 2014  A $3 million grant from The Glenn ... Michigan to establish a national center of excellence in ... Aging Research at U-M will focus on exploiting and ... effects of aging and postpone diseases in animal models. ... help develop medications that may help people live longer, ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, 2014 ... the National Hemophilia Foundation,s (NHF) new three-year initiative, ... to people with hemophilia and their families/caregivers to ... can impede disease management. The curriculum for the ... Your Provider About Pain , focuses on improving ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... TARRYTOWN, N.Y., Nov. 2, 2011 Siemens Healthcare Diagnostics ... a partnership aimed at setting new standards in ... of patients, infectious disease states and potential treatment paths. ... make existing Siemens molecular HIV tests compatible with the recently ...
... world leader in diabetes care, announced today that it has ... (DHF), a non-profit organization that raises diabetes awareness and connects ... of the Drive the Switch program, which has motivated more ... and their doctor about options for insulin delivery, like the ...
Cached Medicine Technology:New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 2New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 2Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 4Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 5Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 6Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 7
(Date:9/18/2014)... ORLANDO, Fla., and DENVER (PRWEB) September 18, 2014 ... office in Orlando. This new office, managed by Todd ... provide health systems in the southeast with the benefits ... without sacrificing the knowledge and advantage of local project ... regional offices, NexCore has expanded its presence across the ...
(Date:9/18/2014)... September 18, 2014 Once again, Hickman’s ... breakfast restaurants around the Valley to celebrate PJs & ... “World Egg Day”: Friday, October 10, 2014. The “breakfast ... locations to benefit Arizona’s Children Association (AzCA) foster care ... dinner at each participating restaurant on October 10 are ...
(Date:9/18/2014)... are trying to learn more about a condition called ... young athletes. In people with sickle cell trait, ... breakdown that can lead to kidney damage and cardiac ... in the United States collapsed and died during training ... "More student-athletes with sickle cell trait have died ...
(Date:9/18/2014)... decades, researchers have tried to develop broadly effective vaccines ... malaria, and tuberculosis. While limited progress has been made ... available that can protect most people from these devastating ... when vaccines just aren,t working? , At Caltech, Nobel ... problem in a different way. Whereas vaccines introduce substances ...
(Date:9/18/2014)... to support private efforts to provide mental health services ... for similar efforts should federal officials decide to expand ... the VA health system, according to a new RAND ... joint project of philanthropic groups and major academic medical ... and other services to veterans and their families. , ...
Breaking Medicine News(10 mins):Health News:NexCore Group Opens Regional Office in Orlando, Florida 2Health News:October 10th Is 6th Annual PJs & Eggs: Hickman’s Family Farms and Breakfast Restaurants Partner to Benefit Arizona Foster Children 2Health News:Scientists Studying Sickle Cell Trait 2Health News:A new way to prevent the spread of devastating diseases 2Health News:A new way to prevent the spread of devastating diseases 3Health News:A new way to prevent the spread of devastating diseases 4Health News:A new way to prevent the spread of devastating diseases 5Health News:Study provides insight about providing private mental health service to veterans 2Health News:Study provides insight about providing private mental health service to veterans 3
... the U.S., demonstrated both the efficacy and ... with nasal symptoms associated with perennial allergic ... today the U.S. Food and Drug Administration (FDA) ... children aged 2-5,years old for the treatment of ...
... unclear, experts say , , MONDAY, Sept. 22 (HealthDay News) ... to take much longer to get to the hospital when ... new study finds. , The finding suggests that patients without ... critical window for time-sensitive care following a heart attack, the ...
... Cyberonics, Inc. (Nasdaq:,CYBX) today announced that its corporate ... The facility incurred no damage from the ... resulting in the Company operating from its,disaster recovery ... returned to normal, including all shipments and production ...
... experience trouble, study finds , , MONDAY, Sept. 22 (HealthDay ... -- which include Crestor, Lipitor, Pravachol and Zocor -- ... Canadian study indicates. , Delirium is a common, and ... of surgery, according to study lead author Dr. Donald ...
... previously unknown mechanism of immunity suggests that there may ... adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at ... (HSPH). The findings, published in the open-access journal ... development of novel pneumococcal vaccines. (The current vaccine, Prevnar, ...
... Pa., Sept. 22 A group of southeastern,Pennsylvania ... on,Thursday, September 25 at 12:00 PM at their ... maternity care crisis in Pennsylvania, and how a,legislative ... State,Representative Mike Vereb (R-Montgomery) and other legislators from,southeastern ...
Cached Medicine News:Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 2Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 3Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 4Health News:Heart Attack Care Often Delayed for the Poor 2Health News:Heart Attack Care Often Delayed for the Poor 3Health News:Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike 2Health News:Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike 3Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 2Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 3Health News:New insights could lead to a better pneumococcal vaccine 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: